To provide our Partners with a single identity for the services and technologies offered across Antitope, PacificGMP, PolyTherics and TCRS we will be changing the names under which they trade to Abzena.
From the 15 March 2016 all employees will be sending emails from an abzena.com email address, and you will begin to see the Abzena name on all documents and presentations. We will also be launching a new website in early June to promote our range of services, technologies and manufacturing capabilities.
The integration of the groups within Abzena will allow for experiences from a wide range of capabilities (from immunological analysis, protein engineering, cell line development, conjugation, chemistry and manufacturing) to be shared with the potential to add further value to our Partners. Abzena will remain committed to client confidentiality and will work on the premise that Partner information will not be shared across groups except where agreed or for routine administrative functions (e.g. billing).
For a period of time Antitope, PolyTherics, TCRS and PacificGMP will remain legal names for contractual, IP and licensing purposes. You therefore do not need to do anything, in particular, no changes to your current documentation will be required.
Abzena provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products. Abzena has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).
- Immunogenicity assessment and immunology studies, protein engineering to create humanized antibodies and deimmunised therapeutic proteins and development of manufacturing cell lines.
- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, gene therapy and cell therapy products, for preclinical and clinical studies.
- Proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals. Contract chemistry and custom synthesis and manufacture of payloads, Abzena is establishing the capability to manufacture ADCs to GMP standards.